Pro106Leu MPL mutation is associated with thrombocytosis and a low risk of thrombosis, splenomegaly and marrow fibrosis

References

• Kikuchi M, Tayama T, Hayakawa H, Takahashi I, Hoshino H, Ohsaka A. Familial thrombocytosis. Br J Haematol. 1995;89(4):900–902. doi:10.1111/j.1365-2141.1995.tb08432.x. PubMed PMID: 7772529.
   PubMed Web of Science ®Google Scholar
• Williams EC, Shahidi NT. Benign familial thrombocytosis. Am J Hematol. 1991;37(2):124–125. doi:10.1002/ajh.2830370211. PubMed PMID: 2069156.
   PubMed Web of Science ®Google Scholar
• Hitchcock IS, Kaushansky K. Thrombopoietin from beginning to end. Br J Haematol. 2014;165(2):259–268. doi:10.1111/bjh.12772. Epub 20140206. PubMed PMID: 24499199.
   PubMed Web of Science ®Google Scholar
• Control of platelet production. N Engl J Med. 1968;278(21):1175–1176. doi:10.1056/NEJM196805232782112. PubMed PMID: 5650969.
   PubMed Web of Science ®Google Scholar
• Grozovsky R, Giannini S, Falet H, Hoffmeister KM. Regulating billions of blood platelets: glycans and beyond. Blood. 2015;126(16):1877–1884. doi:10.1182/blood-2015-01-569129. Epub 20150901. PubMed PMID: 26330242; PubMed Central PMCID: PMC4608239.
   PubMed Web of Science ®Google Scholar
• Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NCC, Berg T, Elena C, Casetti IC, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544–1551. doi:10.1182/blood-2013-11-539098. Epub 20131223. PubMed PMID: 24366362; PubMed Central PMCID: PMC3945864.
   PubMed Web of Science ®Google Scholar
• Liu K, Martini M, Rocca B, Amos CI, Teofili L, Giona F, Ding J, Komatsu H, Larocca LM, Skoda RC, et al. Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica. 2009;94(10):1368–1374. doi:10.3324/haematol.2009.005918. Epub 20090716. PubMed PMID: 19608689; PubMed Central PMCID: PMC2754952.
   PubMed Web of Science ®Google Scholar
• Prouzet-Mauléon V, Montibus B, Chauveau A, Hautin M, Migeon M, Ka C, Laharanne E, Bidet A, Corcos L, Lippert E, et al. A novel thrombopoietin (THPO) mutation altering mRNA splicing in a case of familial thrombocytosis. Br J Haematol. 2020;190(2):e104–e7. doi:10.1111/bjh.16742. Epub 20200519. PubMed PMID: 32430933.
   PubMed Web of Science ®Google Scholar
• Wolber EM, Jelkmann W. Thrombopoietin: the novel hepatic hormone. News Physiol Sci. 2002;17:6–10. doi:10.1152/physiologyonline.2002.17.1.6. Epub 2002/02/01. PubMed PMID: 11821529.
   PubMedGoogle Scholar
• Stockklausner C, Klotter AC, Dickemann N, Kuhlee IN, Duffert CM, Kerber C, Gehring NH, Kulozik AE . The thrombopoietin receptor P106L mutation functionally separates receptor signaling activity from thrombopoietin homeostasis. Blood. 2015;125(7):1159–1169. doi:10.1182/blood-2014-07-587170. Epub 20141223. Epub 20141223.
   PubMed Web of Science ®Google Scholar
• El-Harith E-H, Roesl C, Ballmaier M, Germeshausen M, Frye-Boukhriss H, von Neuhoff N, Becker C, Nürnberg G, Nürnberg P, Ahmed MAM, et al. Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu in the MPL gene. Br J Haematol. 2009;144(2):185–194. doi:10.1111/j.1365-2141.2008.07430.x. Epub 20081119. PubMed PMID: 19036112.
   PubMed Web of Science ®Google Scholar
• Favale F, Messaoudi K, Varghese LN, Boukour S, Pecquet C, Gryshkova V, Defour JP, Albu R-I, Bluteau O, Ballerini P, et al. An incomplete trafficking defect to the cell-surface leads to paradoxical thrombocytosis for human and murine MPL P106L. Blood. 2016;128(26):3146–3158. doi:10.1182/blood-2016-06-722058. Epub 20161110. PubMed PMID: 28034873.
   PubMed Web of Science ®Google Scholar
• Barbara J, Bain I. Dacie and Lewis practical haematology. 12th ed. 9780702066962 I, editor. London (UK): Elsevier Health Sciences; 2016.
   Google Scholar
• John D, Bancroft AS. Bancroft’s theory and practice of histological techniques Eighth edition ed. 9780702068874 I, editor. London (UK): Elsevier; 2019.
   Google Scholar
• Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–5032. doi:10.1182/blood-2011-01-293050. Epub 2011/02/09. PubMed PMID: 21300984; PubMed Central PMCID: PMC3109529.
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Gisslinger H, Finazzi G, Vannucchi AM, Tefferi A. The 2016 revision of WHO classification of myeloproliferative neoplasms: clinical and molecular advances. Blood Rev. 2016;30(6):453–459. doi:10.1016/j.blre.2016.06.001. Epub 2016/06/28. PubMed PMID: 27341755.
   PubMed Web of Science ®Google Scholar
• Thiele J, Krech R, Wienhold S, Simon KG, Zankovich R, Fischer R. The use of the anti-factor VIII method on trephine biopsies of the bone marrow for the identification of immature and atypical megakaryocytes in myeloproliferative diseases and allied disorders. Virchows Archiv B. 1987;54(1):89. doi:10.1007/BF02899200.
   Google Scholar
• Handin R, Lux S, Stossel T. principles and practice of hematology. edition n, editor. Philadelphia, Pa:Lippincott Williams & Wilkins;2003.
   Google Scholar
• Chua CC, Omerod A, Wight J, Juneja S, Zantomio D. Correlation of mutation status and morphological changes in essential thrombocythaemia and myelofibrosis. Pathology. 2018;50(6):671–674. doi:10.1016/j.pathol.2018.02.005. Epub 20180807. PubMed PMID: 30097170.
   PubMed Web of Science ®Google Scholar
• Wilkins BS, Erber WN, Bareford D, Buck G, Wheatley K, East CL, Paul B, Harrison CN, Green AR, Campbell PJ, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood. 2008;111(1):60–70. doi:10.1182/blood-2007-05-091850. Epub 20070920. PubMed PMID: 17885079.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-643544. Blood. 2016;128(3):462-3. doi: 10.1182/blood-2016-06-721662. PubMed PMID: 31659364.
   PubMed Web of Science ®Google Scholar
• Moliterno AR, Williams DM, Gutierrez-Alamillo LI, Salvatori R, Ingersoll RG, Spivak JL. Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. Proc Natl Acad Sci U S A. 2004;101(31):11444–11447. doi:10.1073/pnas.0404241101. Epub 20040721. PubMed PMID: 15269348; PubMed Central PMCID: PMC509220.
   PubMed Web of Science ®Google Scholar
• Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, Satoh A, Tsuboi K, Nitta M, Miyazaki H, Iida S, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103(11):4198–4200. doi:10.1182/blood-2003-10-3471. Epub 20040205. PubMed PMID: 14764528.
   PubMed Web of Science ®Google Scholar
• Teofili L, Giona F, Torti L, Cenci T, Ricerca BM, Rumi C, Nunes V, Foa R, Leone G, Martini M, et al. Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. Haematologica. 2010;95(1):65–70. doi:10.3324/haematol.2009.007542. Epub 20090827. PubMed PMID: 19713221; PubMed Central PMCID: PMC2805752.
   PubMed Web of Science ®Google Scholar
• Al-Harbi T, Al-Zahrani M, Al-Balwi M, Al-Hazmi A, Alsuhaibani A, Aljafn N, Alsumari F, Aleshaiwi L, Alsuhibani A, Alqasim O, et al. Clinical course of myeloproliferative leukaemia virus oncogene (MPL) mutation-associated familial thrombocytosis: a review of 64 paediatric and adult patients. Br J Haematol. 2021;194(5):893–898. doi:10.1111/bjh.17624. Epub 20210615. PubMed PMID: 34131895.
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Viero P, Finazzi G, D’Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;8(3):556–562. doi:10.1200/JCO.1990.8.3.556. PubMed PMID: 2307991.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer. 1990;66(3):549–556. doi:10.1002/1097-0142(19900801)66:3<549::aid-cncr2820660324>3.0.co;2-6. PubMed PMID: 2364366.
   PubMed Web of Science ®Google Scholar
• Bellucci S, Janvier M, Tobelem G, Flandrin G, Charpak Y, Berger R, Boiron M . Essential thrombocythemias. Clinical evolutionary and biological data. Cancer. 1986;58(11):2440–2447. doi:10.1002/1097-0142(19861201)58:11<2440::AID-CNCR2820581115>3.0.CO;2-Y. PubMed PMID: 3768838.
   PubMed Web of Science ®Google Scholar
• Chistolini A, Mazzucconi MG, Ferrari A, la Verde G, Ferrazza G, Dragoni F, Vitale A, Arcieri R, Mandelli F . Essential thrombocythemia: a retrospective study on the clinical course of 100 patients. Haematologica. 1990;75(6):537–540. PubMed PMID: 2098295.
   PubMed Web of Science ®Google Scholar
• Colombi M, Radaelli F, Zocchi L, Maiolo AT. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer. 1991;67(11):2926–2930. doi:10.1002/1097-0142(19910601)67:11<2926::aid-cncr2820671136>3.0.co;2-3. PubMed PMID: 2025858.
   PubMed Web of Science ®Google Scholar
• Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391–2405. doi:10.1056/NEJMoa1312542. Epub 20131210. PubMed PMID: 24325359; PubMed Central PMCID: PMC3966280.
   PubMed Web of Science ®Google Scholar
• Milosevic Feenstra JD, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I, Bagienski K, Kubesova B, Pietra D, Gisslinger B, et al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood. 2016;127(3):325–332. doi:10.1182/blood-2015-07-661835. Epub 20150930. PubMed PMID: 26423830; PubMed Central PMCID: PMC4752213.
   PubMed Web of Science ®Google Scholar
• Cabagnols X, Favale F, Pasquier F, Messaoudi K, Defour JP, Ianotto JC, Marzac C, Le Couédic JP, Droin N, Chachoua I, et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood. 2016;127(3):333–342. doi:10.1182/blood-2015-07-661983. Epub 20151008. PubMed PMID: 26450985.
   PubMed Web of Science ®Google Scholar
• Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NCC, Berg T, Gisslinger B, Pietra D, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–2390. doi:10.1056/NEJMoa1311347. Epub 20131210. PubMed PMID: 24325356.
   PubMed Web of Science ®Google Scholar